Navigation Links
AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan
Date:1/8/2009

TUSTIN, Calif., Jan. 8 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a vertically integrated pharmaceutical company with operations in China and the U.S., announced today it has revised its 2009 Performance and Equity Incentive Compensation Plan for senior management and employees.

Under the terms of the Plan, AMDL has transitioned from a "discretionary cash and options-based bonus plan" to a performance-based, stock and cash incentive plan. Incentives are based on successfully achieving financial targets established by AMDL's Board of Directors.

Plan highlights include:

  • Performance based incentive awards
  • Board-determined quarterly income performance targets
  • Limited cash bonus awards
  • Reaffirmation of AMDL's commitment to not issue discretionary incentive awards

According to Mr. Michael Boswell, independent board member and Chairman of AMDL's Compensation and Audit Committees, "We have made a deliberate decision to establish a more structured compensation plan that directly links our executive and employee compensation to Company performance. In establishing this new plan, we are creating stronger alignment between the interests of our management team, employees, and investors. We feel the modifications made support AMDL's long-term success."

Under AMDL's 2009 Performance and Equity Incentive Compensation Plan, all stock granted to senior executives and employees as incentive compensation will be scheduled to vest only if the Company's meets its strategic goals and specific financial performance targets. AMDL's Board of Directors and Compensation Committee have reviewed and approved the performance targets and Plan outlined above. Detailed information on this revised Plan can be found in AMDL's Form 8-K filed with the Securities and Exchange Commission.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    (Tel :) 206. 310.5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
2. AMDL, Inc. Selected as #1 Small-Cap Stock Pick for 2009
3. Ambulatory Services of America, Inc. Completes Purchase of Majority Interest in Rosa of Georgia, LLC
4. Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
5. Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Product Offering
6. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
7. Blue Cross and Blue Shield of Florida Completes Acquisition of Florida Health Care Plans
8. Hard To Treat Diseases (HTDS) Completes E Europe Merger
9. New Zealand Waynes New Resources Development Co., Ltd. Completes Reverse Merger to Go Public in the U.S.
10. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
11. Smart Financial Credit Union Completes Key FCU Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... ... Miami native and local periodontist Dr. John Paul Gallardo is celebrating ... 1991 that this journey would have taken me into so many learning experiences both ... has pioneered implant dentistry innovation, evolving into an internationally recognized leader in the industry. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... and domain expertise for sponsors and CROs to speed clinical development, has ... (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical supply ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... an agreement to be the preferred physical therapy provider for Derby City CrossFit, ... to Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Liberty attempts to compare student test score performance for the 2015-16 school year ... the state’s voucher programs. Though it highlights important patterns in student test score ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 SW Safety Solutions, ... and comfort, announces the release of the latest advancement ... most recent example of leading edge nitrile glove technology ... for 200% more tactile grip on wet and oily ... durability. With TracTek and a suite of other advanced ...
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
Breaking Medicine Technology: